Novel targets for spinal cord injury related neuropathic pain

Annals of Neurosciences

Volumn 18, Issue 4, 2011, Pages 162-167

  Ahmed, Mostafa M ^a   King, Kevin C ^a   Pearce, Shane M ^a   Ramsey, Melissa A ^a   Miranpuri, Gurwattan S ^a   Resnick, Daniel K ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

MMPS; Neuropathic pain; Spinal cord injury; TIMPS

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CANNABINOID RECEPTOR; COLLAGEN; CYCLIC AMP; ENDOCANNABINOID; GELATINASE A; GELATINASE B; LAMININ; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; NEUROTROPIC AGENT; PROTEOGLYCAN; SYNAPTOPHYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

CELLULAR DISTRIBUTION; CHRONIC PAIN; HUMAN; INFLAMMATION; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PATHOGENESIS; PERIPHERAL NERVE INJURY; PROTEIN EXPRESSION; REVIEW; SPINAL CORD INJURY; TISSUE DISTRIBUTION; TISSUE INJURY;

EID: 80052889917     PISSN: 09727531     EISSN: 09763260     Source Type: Journal    
DOI: 10.5214/ans.0972.7531.1118413     Document Type: Review

References (70)

1. Arai K, Lee SR and Lo EH. Essential role for ERK mitogen-activated protein kinase in matrix metalloproteinase-9 regulation in rat cortical astrocytes. Glia 2003; 43(3): 254-264.
2. Bethea JR, Dietrich WD. Targeting the host inflammatory response in traumatic spinal cord injury. Curr Opin Neurol 2002; 15: 355-60.
3. Lucas SM, Rothwell NJ and Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacol 2006; 147: S232-40.
4. Ransohoff RM, Kivisakk P and Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003; 3: 569-81.
5. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990; 322: 1405-11.
6. Goss JR, O'Malley ME, Zou L, et al. Astrocytes are the major source of nerve growth factor upregulation following traumatic brain injury in the rat. Exp Neurol 1998; 149: 301-9.
7. Heese K, Hock C and Otten U. Inflammatory signals induce neurotrophin expression in human microglial cells. J Neurochem 1998; 70: 699-707.
8. Miletic G, Miletic V. Increases in the concentration of brain derived neurotrophic factor in the lumbar spinal dorsal horn are associated with pain behavior following chronic constriction injury in rats. Neurosci Lett 2002; 319: 137-40.
9. Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 2006; 29: 507-38.
10. Coull JA, Beggs S, Boudreau D, et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 2005; 438: 1017-21.
11. Guo W, Robbins MT, Wei F, et al. Supraspinal brain-derived neurotrophic factor signaling: a novel mechanism for descending pain facilitation. J Neurosci 2006; 26: 126-37.
12. Hathway GJ, Fitzgerald M. Time course and dose-dependence of nerve growth factor- induced secondary hyperalgesia in the mouse. J Pain 2006; 7: 57-61.
13. Matayoshi S, Jiang N, Katafuchi T, et al. Actions of brain-derived neurotrophic factor on spinal nociceptive transmission during inflammation in the rat. J Physiol 2005; 569: 685-95.
14. Kawasaki Y, Xu ZZ, Wang X, et al. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat.Med 2008; 14(3): 331-336.
15. Hausmann ON. Post-traumatic inflammation following spinal cord injury. Spinal Cord 2003; 41: 369-78.
16. Finnerup NB, Jensen TS. Mechanisms of disease: mechanism-based classification of neuropathic pain-a critical analysis. Nat Clin Pract Neurol 2006; 2: 107-15.
17. Tachibana T, Noguchi K and Ruda MA. Analysis of gene expression following spinal cord injury in rat usuing complementary DNA microarray. Neurosci Lett 2002; 327(2): 133-7.
18. Pearce, SM, Ramsey, MA, et al. Regulation and fuction of Matrix Matalloproteins in nervous system injury and neuropathic pain. Annals of Neurosciences 2008; 15: 94-105.
19. Goussev S, Hsu JY, Lin Y, et al. Differential temporal expression of matrix metalloproteinases after spinal cord injury: relationship to revascularization and wound healing. J.Neurosurg 2003; 99(2 Suppl): 188-197.
20. Hsu JY, McKeon R, Goussev S, et al. Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury. J.Neurosci 2006; 26(39): 9841-9850.
21. Jones TB, Ankeny DP and Guan Z, et al. Passive or active immunization with myelin basic protein impairs neurological function and exacerbates neuropathology after spinal cord injury in rats. J Neurosci 2004; 24: 3752-61.
22. Klusman I, Schwab ME. Effects of pro-inflammatory cytokines in experimental spinal cord injury. Brain Res 1997; 762: 173-84.
23. Pannu R, Christie DK, Barbosa E, et al. Posttrauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury. J.Neurochem 2007; 101(1): 182-200.
24. Ho A, Blum M. Regulation of astroglial-derived dopaminergic neurotrophic factors by interleukin-1 beta in the striatum of young and middle-aged mice. Exp Neurol 1997; 148: 348-59.
25. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia 2002; 39(3): 279-291.
26. Conti A, Miscusi M, Cardali S, et al. Nitric oxide in the injured spinal cord: synthases cross-talk, oxidative stress and inflammation. Brain Res Rev 2007; 54: 205-18.
27. Noble LJ, Donovan F, Igarashi T, et al. Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J.Neurosci 2002; 22(17): 7526-7535.
28. Hurlbert RJ. Strategies of medical intervention in the management of acute spinal cord injury. Spine 2006; 31: S16-21.
29. Pizzi MA, Crowe MJ. Matrix metalloproteinases and proteoglycans in axonal regeneration. Exp.Neurol 2007; 204(2): 496-511.
30. Mun-Bryce S, Lukes A, Wallace J, et al. Stromelysin-1 and gelatinase A are upregulated before TNF-alpha in LPS-stimulated neuroinflammation. Brain Res 2002; 933(1): 42-49.
31. Bracken MB, Collins WF, Freeman DF, et al. Efficacy of methylprednisolone in acute spinal cord injury. JAMA 1984; 251: 45-52.
32. Del Zoppo GJ, Milner R, Mabuchi T, et al. Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke 2007; 38(2 Suppl): 646-651.
33. Yezierski RP. Spinal cord injury: a model of central neuropathic pain. Neurosignals 2005; 14: 182-93
34. Wang X, Mori T, Jung JC, et al. Secretion of matrix metalloproteinase-2 and -9 after mechanical trauma injury in rat cortical cultures and involvement of MAP kinase. J.Neurotrauma 2002; 19(5): 615-625.
35. Vecil GG, Larsen PH, Corley SM, et al. Interleukin- 1 is a key regulator of matrix metalloproteinase-9 expression in human neurons in culture and following mouse brain trauma in vivo. J.Neurosci. Res 2000; 61(2): 212-224.
36. Hagenacker T, Ledwig D and Busselberg D. Feedback mechanisms in the regulation of intracellular calcium ([Ca2+]i) in the peripheral nociceptive system: role of TRPV-1 and pain related receptors. Cell Calcium 2008; 43(3): 215-227.
37. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br.J.Pharmacol 2008; 153(2): 319-334.
38. Karin M, Zheng-gang L and Ebrahim Z. AP-1 function and regulation. Current Opinion in Cell Biology 1997; 9(2): 240-246.
39. Reunanen N, Li SP, Ahonen M, et al. Activation of p38 alpha MAPK enhances collagenase-1 (matrix metalloproteinase (MMP)-1) and stromelysin-1 (MMP-3) expression by mRNA stabilization. J.Biol. Chem 2002; 277(35): 32360-32368.
40. Botelho FM, Edwards DR and Richards CD. Oncostatin M stimulates c-Fos to bind a transcriptionally responsive AP-1 element within the tissue inhibitor of metalloproteinase- 1 promoter J Biol Chem. 1998; 273(9): 5211-8.
41. Tong L, Smyth D, Kerr C, et al. Mitogen-activated protein kinases Erk1/2 and p38 are required for maximal regulation of TIMP-1 by oncostatin M in murine fibroblasts. Cell.Signal. 200; 16(10): 1123-1132.
42. Ramer R, Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J.Natl.Cancer Inst. 2008; 100(1): 59-69.
43. Walczak JS, Pichette V, Leblond F, et al. Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes. J.Neurosci.Res 2006; 83(7): 1310-1322.
44. Costa B, Colleoni M, Conti S, et al. Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. Br.J.Pharmacol 2004; 141(1): 4-8.
45. Croxford JL. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 2003;17(3): 179-202.
46. Guindon J, Walczak JS and Baulieu P. Recent advances in the pharmacological management of pain. Drugs 2007; 67(15): 2121-33
47. Herzberg U, Eliav E and Bennett GJ, et al. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci.Lett 1997; 221(2-3): 157-160.
48. Patwardhan AM, Jeske NA, Price TJ, et al. The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc.Natl. Acad.Sci.U.S.A. 2006;103(30): 11393-11398.
49. DomBourian MG, Turner NA, Gerovac TA, et al. B1 and TRPV-1 receptor genes and their relationship to hyperalgesia following spinal cord injury. Spine 2006; 31: 2778-82.
50. Rajpal S, Gerovac TA, Turner NA, et al. Antihyperalgesic effects of vanilloid-1 and bradykinin-1 receptor antagonists following spinal cord injury in rats. J Neurosurg Spine 2007; 6: 420-4.
51. Rice AS, Farquhar-Smith WP and Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot. Essent.Fatty Acids 2002; 66(2-3): 243-256.
52. Hermann H, De Petrocellis, L Bisogno T, et al. Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptormediated response. Cell Mol Life Sci 2003; 60: 607-16.
53. Hama A, Sagen J. Antinociceptive effect of cannabinoid agonist WIN 55, 212-2 in rats with a spinal cord injury. Exp Neurol 2007; 204: 454-7.
54. Rajpal S, Gerovac TA, Turner NA, et al. Selective inhibition of thermal hyperalgesia following spinal cord injury with selective B1 receptor antagonists versus TRPV1 antagonists. J Neurosurg Spine 2007.
55. Sagar DR, Smith PA, Millns PJ, et al. TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat. Eur J Neurosci 2004; 20: 175-84.
56. Rodriguez Parkitna J, Korostynski M, Kaminska-Chowaniec D, et al. Comparison of gene expression profiles in neuropathic and inflammatory pain. J.Physiol.Pharmacol. 2006; 57(3): 401-414.
57. Cao J, Zucker S. Biology and chemistry of metalloproteinases (MMPs). Retrieved 2008, from Abcam plc: http://www.abcam.com/index.html?pageconfig=resource&rid=11034&pid=10628 2008.
58. Sommer C, Schmidt C, George A, et al. A metalloprotease-inhibitor reduces pain associated behavior in mice with experimental neuropathy. Neurosci.Lett 1997; 237(1): 45-48.
59. Nagase H, Woessner JF, Jr. Matrix metalloproteinases. J.Biol.Chem 1999 Jul 30; 274(31): 21491-21494.
60. Fleming JC, Norenberg MD, Ramsay DA, et al. The cellular inflammatory response in human spinal cords after injury. Brain 2006;129(Pt 12): 3249-3269.
61. Moalem G, Xu K and Yu L. T lymphocytes play a role in neuropathic pain following peripheral nerve injury in rats. Neuroscience 2004; 129: 767-77.
62. Yang JY, Kim HS and Lee JK. Changes in nitric oxide synthase expression in young and adult rats after spinal cord injury. Spinal Cord 2007.
63. Campbell LG, Ramachandran S, Liu W, et al. Different Roles for Matrix Metalloproteinases- 2 and Matrix Metalloproteinase- 9 in the Pathogenesis of Cardiac Allograft Rejection. American Journal of Transplantaion 2004;(5): 517.
64. Wang Y, Deng XL, Xiao XH, et al. A non-steroidal anti-inflammatory agent provides significant protection during focal ischemic stroke with decreased expression of matrix metalloproteinases. Curr.Neurovasc Res 2007; 4(3): 176-183.
65. Yamaguchi M, Jadhav V, Obenaus A, et al. Matrix metalloproteinase inhibition attenuates brain edema in an in vivo model of surgically-induced brain injury. Neurosurgery 2007 Nov; 61(5): 1067-75; discussion 1075-6.
66. Hooper NM, Karran EH and Turner AJ. Membrane protein secretases. Biochem. J 1997; 321 (Pt 2)(Pt 2): 265-279.
67. Solorzano CC, Ksontini R, Pruitt JH, et al. Involvement of 26-kDa cell-associated TNF-alpha in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. J.Immunol 1997; 158(1): 414-419.
68. Wojtowicz-Praga S. Clinical potential of matrix metalloprotease inhibitors. Drugs R.D. 1999 Feb; 1(2): 117-129.l
69. Dittmar M, Kiourkenidis G, Horn M, et al. Cerebral ischemia, matrix metalloproteinases, and TNF-alpha: MMP inhibitors may act not exclusively by reducing MMP activity. Stroke 2004; 35(7): e338-40; author reply e338-40.
70. Pfefferkorn T, Rosenberg GA. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 2003; 34(8): 2025-2030.